Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD2 | P13995 | 2/20 | 0.74 |
| ▸ | MTHFD1 | P11586 | 2/20 | 0.74 |
| ▸ | DHFR | P00374 | 2/20 | 0.61 |
| ▸ | MTR | Q99707 | 1/20 | 0.60 |
| ▸ | GART | P22102 | 6/20 | 0.57 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.57 |
| ▸ | ATIC | P31939 | 4/20 | 0.56 |
| ▸ | TYMS | P04818 | 1/20 | 0.54 |
| ▸ | FPGS | Q05932 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Folitixorin SCHEMBL4108452 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Arfolitixorin SCHEMBL29616436 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL16467076 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL50782 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL258730 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL3180668 | 1.00 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL4537420 | 0.99 | MTHFD2 (0.73) | MTHFD2MTHFD1DHFRMTRGART | |
| Arfolitixorin SCHEMBL30694324 | 0.99 | MTHFD2 (0.73) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL29556725 | 0.98 | MTHFD2 (0.72) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL9430909 | 0.97 | MTHFD2 (0.70) | MTHFD2MTHFD1DHFRMTRGART |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 515 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260063623-A1 | METHODS OF ASSESSING METABOLIC FLUX | UNIV MICHIGAN REGENTS (US) | 2026-03-05 | — | — | US | claimed |
| US-20260048054-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-02-19 | — | — | US | claimed |
| US-12527796-B2 | [6R]-MTHF—an efficient folate alternative in 5-fluorouracil based chemotherapy | ISOFOL MEDICAL AB (SE) | 2026-01-20 | — | — | US | claimed |
| US-12336994-B2 | Alpha polyglutamated tetrahydrofolates and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-06-24 | — | — | US | claimed |
| EP-4536184-A1 | CONCENTRATED SOLUTIONS COMPRISING SODIUM 5,10-METHYLENE-(6R)- TETRAHYDROFOLATE | Merck Patent GmbH (DE) | 2025-04-16 | — | — | EP | claimed |
| EP-4536188-A1 | STABLE LYOPHILISATES COMPRISING 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID | Merck Patent GmbH (DE) | 2025-04-16 | — | — | EP | claimed |
| EP-4534088-A1 | ARFOLITIXORIN FOR USE IN VITAMIN B6-ENHANCED, 5-FLUOROURACIL-BASED CHEMOTHERAPY OF CARCINOMAS | Isofol Medical AB (SE) | 2025-04-09 | — | — | EP | claimed |
| US-20250064736-A1 | GAMMA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-02-27 | — | — | US | claimed |
| US-20240415837-A1 | PHARMACOLOGIC MODULATION OF 5-FLUOROURACIL BY FOLINIC ACID AND VITAMIN B6 FOR THE TREATMENT OF PATIENTS WITH CARCINOMA | MACHOVER DAVID (FR) | 2024-12-19 | — | — | US | claimed |
| US-20240350495-A1 | [6R]-MTHF IN B6 ENHANCED 5-FU BASED CHEMOTHERAPY OF CARCINOMA | ISOFOL MEDICAL AB (SE) | 2024-10-24 | — | — | US | claimed |
| EP-4114399-A1 | FOLATE PREPARATIONS FOR THE TREATMENT OF OCULAR DISEASES | Aprofol AG (CH) | 2023-01-11 | — | — | EP | claimed |
| EP-3735267-B1 | ADMINSITRATION OF MULTIPLE BOLUSES OF [6R] MTHF IN A 5-FLUOROURACIL-BASED CHEMOTHERAPY | ISOFOL MEDICAL AB (SE) | 2022-09-14 | — | — | EP | claimed |
| US-20210346381-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2021-11-11 | — | — | US | claimed |
| US-20210128469-A1 | GAMMA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | L.E.A.F HOLDINGS GROUP LLC | 2021-05-06 | — | — | US | claimed |
| CN-111971047-A | Gamma polyglutamated tetrahydrofolic acid and application thereof | L.E.A.F.控股集团公司 | 2020-11-20 | — | — | CN | claimed |
| CN-111936146-A | Alpha polyglutamated tetrahydrofolic acid and application thereof | L.E.A.F.控股集团公司 | 2020-11-13 | — | — | CN | claimed |
| CN-106103698-B | Chemically defined cell culture medium additives | 汉阳大学校产学协力团 | 2020-08-21 | — | — | CN | claimed |
| US-20170009199-A1 | CHEMICALLY DEFINED CELL CULTURE MEDIA ADDITIVE | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) (KR) | 2017-01-12 | — | — | US | claimed |
| CN-106103698-A | The additive of the cell culture medium that chemical composition determines | 汉阳大学校产学协力团 | 2016-11-09 | — | — | CN | claimed |
| EP-1724356-B1 | Method for producing ß-hydroxy amino acid and enzyme used therefore | AJINOMOTO KK (JP) | 2009-09-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12336994-B2 | Alpha polyglutamated tetrahydrofolates and uses thereof | DHFR, FPGS, MTHFD1 | MTHFD2 6/4885MTHFD1 3/4885DHFR 1/4885 |
| US-20210128469-A1 | GAMMA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | FPGS, DHFR, MTHFD1 | MTHFD2 6/4885MTHFD1 3/4885DHFR 2/4885 |
| US-20260063623-A1 | METHODS OF ASSESSING METABOLIC FLUX | PC, SLC2A1, SLC2A4 | MTHFD2 733/4885MTHFD1 750/4885DHFR 2642/4885 |
| US-20260048054-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | FOLR2, FOLR1, FPGS | MTHFD2 7/4885MTHFD1 4/4885DHFR 5/4885 |
| US-20250064736-A1 | GAMMA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | FPGS, DHFR, MTHFD1 | MTHFD2 6/4885MTHFD1 3/4885DHFR 2/4885 |
| US-12527796-B2 | [6R]-MTHF—an efficient folate alternative in 5-fluorouracil based chemotherapy | MTHFD1, MTHFD2, FOLR1 | MTHFD2 2/4885MTHFD1 1/4885DHFR 5/4885 |
| US-20210346381-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | DHFR, FPGS, MTHFD1 | MTHFD2 6/4885MTHFD1 3/4885DHFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.